Treatment and control of benign prostatic hyperplasia (BPH) in patients with an enlarged prostate in order to: reducing the size (regression) of an enlarged gland, improving urine outflow, and reducing symptoms associated with BPH; reducing the risk of acute urinary retention and the need for surgery, including transurethror-resection of the prostate and prostatectomy.
Main active ingredient: finasteride.
Excipients included in the preparation: lactose, cellulose, starch, povidone, starch glycolate, magnesium stearate, tal, hypromellose, titanium dioxide, simethicone, etc.
It is produced in the form of tablets, in a dosage of 5 mg of finasteride in each.
This drug Penester belongs to a group of drugs that treat benign prostatic hypertrophy.
Finasteride is the main active component of the drug, which is a testosterone 5-alpha reductase inhibitor (type II). This substance is an intracellular enzyme, due to which testosterone is converted into the androgen dihydrotestosterone (the main cause of this type of prostatic hyperplasia), which is a more active androgen.
Finasteride has the property with a high degree of effectiveness to reduce the level of dihydrotestosterone, both circulating and intraprostatic. The use of this drug helps to reduce urinary retention in acute form by more than half after 4 years of treatment. The risks of surgery are reduced over the same period by 50%.
Also, there is a regression of the size of the prostate by 1/5, the rate of urine outflow increases significantly. The risks of further progression of this disease are reduced by 67%.
Studies in the United States have shown that regular use of this drug for benign prostatic hypertrophy reduces the risk of prostate cancer by 25%.
This drug Penester is used to treat and control benign prostatic hyperplasia in patients with an enlarged prostate. The use of the drug allows you to achieve:
- reduction in the size (regression) of the enlarged gland;
- improving the outflow of urine;
- reduction of symptoms associated with this type of hyperplasia;
- to reduce the risk of acute urinary retention and the need for surgical intervention, including transurethroresection of the prostate gland and prostatectomy.
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.
Application during pregnancy and lactation
This drug is not used in the treatment of pregnant women.
If it is necessary to take the drug during breastfeeding, then during treatment, lactation should be suspended.
Method of administration and dosage
Penester is intended for regular long-term use. The recommended dosage is 5 mg (1 tablet), which is taken once a day, preferably at the same time of the day.
Reception is made regardless of food consumption.
It can be taken in combination, together with the drug doxazosin (alpha blocker).
The course of treatment can last for many months as well as several years. The exact timing of treatment depends on the effectiveness of the drug, which are determined using diagnostic studies, on an individual basis.
The effectiveness is assessed at least once every 6 months.
An increase in dosage does not increase efficacy.
Elderly patients, as well as patients with renal and hepatic insufficiency, do not need dosage adjustment.
Reported cases of overdose (400 mg at a time and 80 mg daily for 3 months) did not cause side effects.
There are no recommendations for overdose neutralization.
Possible side effects:
- erectile dysfunction, decreased libido (often), – usually go away after the end of treatment;
- allergic reactions – rash, itching, urticaria, Quincke’s edema;
- depression, heart palpitations;
- increased levels of liver enzymes;
- impotence, ejaculation disorder, breast tenderness and enlargement, breast cancer, testicular pain, sperm quality abnormalities;
- decrease in ejaculate.
Storage conditions and periods
The shelf life is up to 3 years.
Does not require special storage conditions.